For people considering IVF after 40, the central challenge is not simply becoming pregnant but finding an embryo that can lead to a healthy birth and managing the pregnancy safely; Dr Elias Tsakos, FRCOG, Medical Director at Embryoclinic in Thessaloniki, Greece, describes treatment as a careful process of testing, embryo selection and close medical supervision. Fertility declines with age as ovarian reserve decreases and oocyte quality worsens. At the same time, miscarriage and pregnancy complications become more likely.
That does not mean a successful outcome is out of reach. With appropriate evaluation, laboratory techniques and antenatal care, many women over 40 can still have a healthy baby. The route may be more demanding than it would be in the twenties or thirties, and patients may need to consider more than one treatment strategy.
Why age changes IVF outcomes
Age affects several stages of reproduction. Fewer eggs may be available during stimulation, and the eggs that remain are more likely to contain abnormal numbers of chromosomes. An embryo with abnormal chromosomes is described as aneuploid.
The chance of aneuploidy rises over the age of 35 and becomes even more pronounced over the age of 38. This helps explain why an IVF cycle can produce eggs or embryos without producing a pregnancy that continues to live birth. A transfer may fail to implant, or a pregnancy may end in miscarriage because the embryo has abnormal DNA.
The uterus and the rest of the body also matter. Implantation rates decline with age, while obstetric outcomes become more challenging. Pregnancies after 40 are considered high-risk compared with pregnancies in the twenties or thirties and require careful antenatal and obstetric management.
Lifestyle factors can add to the cumulative effects of ageing. Smoking, diet and a lack of exercise may all have negative effects by this stage of life. These factors do not explain every unsuccessful IVF cycle, but they belong in the broader assessment before treatment begins.
Begin with a full pre-IVF assessment
IVF should not be viewed as a single procedure that begins and ends with embryo transfer. Treatment typically starts with pre-IVF testing, followed by ICSI, IVF or other laboratory techniques when appropriate. The aim is to understand the ovaries, the uterus, the embryos and the general health factors that may affect pregnancy.
A practical evaluation may include:
- Assessment of ovarian reserve and the response expected from stimulation
- High-resolution or 3D ultrasound of the uterus
- Hysteroscopy when the uterine cavity needs direct examination
- Hormonal and metabolic testing
- Evaluation for conditions such as endometriosis, severe pelvic inflammatory disease or hydrosalpinges when the history or symptoms suggest them
The uterus deserves particular attention after 38 or 40. Conditions such as hyperplasia, polyps and congenital abnormalities may be more likely, and treating a uterine abnormality can improve the chance of implantation in selected patients.
Hysteroscopy allows the uterine cavity to be examined and, when needed, treated. Laparoscopy may be used to investigate disease outside the uterus, including endometriosis or damage associated with pelvic inflammatory disease. Robotic surgery is used mainly for multiple fibroids and endometriosis in the described practice and may be preferred when highly precise suturing is required.
Why embryo testing may matter
Preimplantation genetic testing for aneuploidy, commonly called PGT-A, is particularly relevant when age makes abnormal embryos more likely. It is performed on embryos created through IVF before an embryo is selected for transfer.
The purpose is to identify embryos with abnormal chromosome numbers before transfer. Reported advantages include higher embryo-transfer success rates, lower miscarriage rates, less delay to an ongoing pregnancy, fewer genetic anomalies in children, more single-embryo transfers and lower multiple-pregnancy rates.
PGT-A cannot create more eggs or improve the quality of an egg that has already been retrieved. Its role is to help distinguish among the embryos available. For a woman in her early forties, the chance of an abnormal embryo may be at least 50%, making the transfer of untested embryos more difficult to interpret. If an untested embryo fails to implant or results in miscarriage, the underlying reason may remain unknown.
When a patient is producing good-quality day-5 embryos, testing can help avoid transferring an embryo that is unlikely to produce a healthy pregnancy. The risks of transferring an abnormal embryo include failed implantation, miscarriage, an ongoing pregnancy with an abnormal fetus or the birth of an unhealthy child. A miscarriage may also affect the uterus and endometrium through inflammation, infection or an intervention.
PGT-A is not necessarily appropriate for every patient. It is viewed as clearly indicated in women in their late thirties and forties and in younger women with failed IVF attempts or miscarriages. The broader treatment plan still depends on the number and quality of embryos available.
Recurrent implantation failure requires a wider search
Repeated failed transfers do not automatically mean that the endometrium is too thin. If several euploid embryos have failed to implant, the uterine lining should be investigated thoroughly, but the search should not stop there.
Possible evaluations include:
- Hysteroscopy with a biopsy
- Testing for chronic endometritis, or persistent inflammation of the uterine lining
- Endometrial microbiome testing using next-generation sequencing
- Laparoscopy to assess endometriosis, severe pelvic inflammatory disease or hydrosalpinges
- Thyroid hormones, testosterone and metabolic testing for insulin resistance or prediabetes
The endometrial microbiome is a newer area of investigation. Changes may be relevant during perimenopause, which many women enter in their early forties. If testing is performed, it should be reliable, and any Lactobacillus product should come from a reputable provider using the appropriate strains.
Metabolic factors can also be overlooked. Evaluation may include fasting glucose, insulin, cortisol, insulin resistance, metabolic syndrome and the triglycerides-to-high-density-lipoproteins ratio. Immunology may be considered, although the evidence for some immune-based approaches is not overwhelming.
The transfer itself matters as well. For someone who ovulates regularly, a natural-cycle frozen embryo transfer may be considered before moving to a medicated cycle. Experienced clinicians and laboratory staff should manage embryo handling and transfer. Embryo glue may also be considered in selected cases.
Scar defects and other uterine problems should be mapped first
A uterine scar defect can interfere with implantation and may create risks if pregnancy occurs. The first step is to map the defect accurately with a 3D or 4D ultrasound scan. This can measure the myometrium, including the thickness at its thinnest point, as well as the depth and width of the defect.
MRI is sometimes used but is not routine in every case. Imaging is followed by hysteroscopy, which provides a direct view of the uterine cavity. The information from both examinations helps determine whether repair is needed before pregnancy.
A large defect measuring 1.8 centimetres and 1.5 millimetres would probably be repaired before attempting pregnancy. The purpose is to avoid beginning a pregnancy with a known structural concern that could have been corrected in advance.
Some defects can be repaired vaginally from below. If the defect is too high or cannot be reached that way, a combination of hysteroscopy and robotic surgery may be used. Robotic surgery is considered more accurate than laparoscopy for the fine suturing required in this type of repair.
Using your own eggs versus donor eggs
Using a patient’s own eggs remains the first priority when that is her preference and when eggs can still be retrieved. Treatment may involve natural cycles, mild stimulation, dual stimulation, different medication protocols, clomiphene and, when there is an indication, ovarian platelet-rich plasma, or ovarian PRP.
Evidence for ovarian rejuvenation remains weaker and equivocal. A treatment that does not show a clear benefit across all patients may still help a particular subgroup, but patients should understand the uncertainty before proceeding.
For women approaching the upper end of reproductive age, IVF with their own eggs may involve several attempts rather than one cycle. If a healthy follicle is present, egg collection may be attempted. Dual stimulation continues ovarian stimulation after the first collection and allows another collection about ten to twelve days later, which may be useful when travel or time is a concern.
As long as a woman is ovulating and having periods, a healthy egg is still possible. However, the likelihood of obtaining a chromosomally normal embryo becomes very small with advancing age. Day-5 embryos have been seen from eggs collected at 49 years and 11 months, but the chance of a normal euploid embryo at that stage is extremely small.
The option of using one’s own eggs does not remain open indefinitely. The stated upper age limit for attempting IVF with own eggs is 50, while egg donation remains an option at ages 50, 51, 52, 53 and 54. The decision to continue with own eggs or move to donor eggs should be made jointly by the patient and the medical team, rather than imposed by a doctor.
For some patients, retaining a genetic connection is the overriding priority. For others, reducing the time to pregnancy matters more. Oocyte donation or embryo donation may offer a clearer route when treatment with a patient’s own genetic material has been exhausted.
Donor sperm and donor eggs
Donor sperm and donor eggs can reduce the genetic risks associated with older reproductive material. The source notes describe donor material as genetically safer than using a woman’s own eggs when she is older than 35 or a man’s own sperm when he is older than 40.
Donors undergo genetic screening, although no testing can identify every possible condition. Some of the tests used for donors may never have been performed on patients themselves. Patients using donor sperm should remain in contact with the sperm bank because new information about a donor can emerge over time.
The concern is not only the quality of genetic screening. The distribution of one donor’s sperm to a large number of families can also matter, because it affects the number of offspring connected to that donor. In Greece, limits exist on how many families and how many times an egg donor can donate: a maximum of six times for 10 families is described. Regulation of the number of offspring is therefore a central consideration.
When surrogacy enters the discussion
If problems affecting the uterus cannot be overcome, gestational surrogacy may be considered. In Greece, it is available for medical reasons rather than social reasons and requires a court order before IVF begins.
Uterus transplantation was also described as an ambitious option that began about eleven or twelve years ago in Sweden and has since spread to many countries, including the UK. It remains distinct from the more established fertility treatments used in routine IVF planning.
For most patients, the immediate focus is more practical: determine whether the uterus can safely support pregnancy, correct problems when possible and choose the most appropriate embryo source. A pregnancy after 40 usually requires a large medical team and close monitoring, but modern antenatal care and delivery management allow many women to achieve a healthy outcome.
Final Thoughts
IVF after 40 is more likely to require patience, testing and difficult decisions than IVF at a younger age. The main barriers may involve egg number, embryo chromosomes, implantation, uterine structure or the health demands of pregnancy itself.
Patients can begin by asking for a complete assessment rather than moving directly to transfer. That may include ovarian testing, uterine imaging, hysteroscopy, metabolic evaluation and a clear discussion of whether PGT-A, donor material or surgery belongs in the plan.
The outlook is challenging but not hopeless. With diagnostic and therapeutic options, many women over 40 who are prepared to consider the available routes can still leave treatment with at least one healthy baby at home.
